Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NEOTHERAPEUTICS (NEOT) (NEOTW) -- Ignore unavailable to you. Want to Upgrade?

To: IMPRISTlNE who wrote (470)	6/6/1998 3:13:00 PM
From: NeuroInvestment	Read Replies (1) \| Respond to of 705

There is a good point here but also an area of confusion. The quote referred to was not from Glasky, but from a previous poster who claimed to have talked to clinical settings in Canada where AIT-082 was tried. I have previously noted that there were aspects to that post that raise questions as to its validity. That is separate from whatever Glasky did or did not say in Italy. The one overlapping comment attributed to him had to do with AD patients speaking again. You are correct in noting what would be considered the distinction between semantic/episodic memory (facts and events) which is lost in AD, versus procedural memory (how to carry out learned activities) which is not lost in AD until the very last stages (where it may be the loss of action initiation that is responsible). These types of memory are controlled by different areas of the brain...the famous patients who had bilateral temporal lobectomies have no recall of events, but can learn and repeat action sequences. Thus the point raised does indicate that the poster in question was either ill-informed or a hoax; but don't blame Glasky. The memory testing that was conducted in the Canadian trial was of semantic memory, as is the much more detailed neuropsych assessment being used in the Phase II trial. NeuroInvestment (www.neuroinv.com)